Analytical Data
-
Gene name
TAL1
- Application
-
Alternative Names
SCL; TCL5; BHLHA17; Stem cell protein; T-Cell Leukemia/Lymphoma Protein 5; Class A basic helix-loop-helix protein 17
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P17542
-
Expression Region
Pro29~Arg331
-
Molecular Weight
35kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TAL1, also known as T-cell acute lymphocytic leukemia protein 1, is a transcription factor that plays a crucial role in hematopoiesis and the development of the immune system. Its dysregulation is implicated in various hematological malignancies, particularly T-cell acute lymphoblastic leukemia (T-ALL). The study of TAL1 recombinant proteins has become a focal point for understanding its functional mechanisms in cellular processes such as differentiation and proliferation. By analyzing TAL1's interactions with other transcription factors and its downstream target genes, researchers aim to elucidate the pathways involved in leukemia development and progression. Additionally, TAL1's role in chromatin remodeling and gene expression regulation highlights its potential as a therapeutic target for T-ALL. Due to the complexity of TAL1's regulatory networks, creating recombinant proteins that accurately mimic its natural function is essential for high-throughput screening and drug discovery efforts. This research not only enhances our understanding of TAL1 in normal and malignant hematopoiesis but also paves the way for innovative treatment strategies that could improve patient outcomes in leukemia.
